Nov. 19, 2012
-- Due to an influx of buyers wishing to acquire hospices in major-metropolitan areas and the supply not matching the demand, Vallexa will now offer a free valuation and research services as to whether a hospice acquisition would benefit companies considering divesting in 2013.
Due to the increase in demand, Vallexa has also expanded their valuation team. A larger team means additional professionals bringing their background and experience to the transaction which benefits both the hospice seller and potential hospice buyer. Their valuation determination is thorough and inclusive of the unique factors affecting the hospice industry. Vallexa says they will likely assess over a dozen hospice companies this week alone on behalf of their clients.
Vallexa is said to be unique among valuation specialists in that they have direct experience from their registered strategic and financial hospice buyers as well as a decade of their own transactional data to draw upon. They are experts in the field because they see what the newest market trends are and are able to act upon them. The result is a benefit of real world knowledge when assessing and valuing a hospice company.
Vallexa determines each valuation using the results of several analyses such as a cash flow assessment, comparable transaction analysis, and others. They then adjust the value to reflect specific aspects of a proposed transaction. Vallexa applies all of the adjustments as appropriate to generate a real-world assessment of the value of the company and determine your company's current "Most Likely Selling Price", all at no cost to the potential seller. Vallexa says that by offering the valuation at no cost, there is no risk to the seller in researching what the potential benefit to a transaction might be.